Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 1, 2013, Pages

  Freixa, Xavier ^a   Almasood, Ali S ^a   Khan, Sohail Q ^a   MacKie, Karen ^a   Osten, Mark ^a   Ing, Douglas ^a   Overgaard, Christopher B ^a   Horlick, Eric M ^a   Seidelin, Peter H ^a   Džavík, Vladimír ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

different stent; drug eluting stents; in stent restenosis; repeated revascularization; same stent

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; RETREATMENT; REVASCULARIZATION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; ONTARIO; PACLITAXEL; PATIENT SELECTION; PROSTHESIS FAILURE; REGISTRIES; RETREATMENT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84871825850     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24291     Document Type: Article

References (29)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
3. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A,. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA 2005; 293: 165-171.
4. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The TAXUS V ISR randomized trial. JAMA 2006; 295: 1253-1263.
5. Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 2006; 47: 2152-2160.
6. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schomig A, Kastrati A,. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010; 55: 2710-2716.
7. Abe M, Kimura T, Morimoto T, Taniguchi T, Yamanaka F, et al. Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry. Circulation 2010; 122: 42-51.
8. Mishkel GJ, Moore AL, Markwell S, Shelton MC, Shelton ME,. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 2007; 49: 181-184.
9. Garg S, Smith K, Torguson R, Okabe T, Slottow TL, et al. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv 2007; 70: 9-14.
10. Liistro F, Fineschi M, Grotti S, Angioli P, Carrera A, Ducci K, Gori T, Falsini G, Pierli C, Bolognese L,. Long-term clinical outcome of alternative treatment strategies for drug-eluting stents restenosis. EuroIntervention 2009; 5: 454-459.
11. Tagliareni F, La Manna A, Saia F, Marzocchi A, Tamburino C,. Long-term clinical follow-up of drug-eluting stent restenosis treatment: Retrospective analysis from two high volume catheterisation laboratories. EuroIntervention 2010; 5: 703-708.
12. Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Babic R, et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J 2007; 153: 354-359.
13. Chevalier B, Fajadet J, CRISTAL-Investigators. 2010. CRISTAL: A Prospective Randomized Trial of Sirolimus-Eluting Stents Compared to Balloon Angioplasty for Restenosis of Drug-Eluting Coronary Stents. Washington: Transcatheter Cardiovascular Therapeutics.
14. Mejia J, Ruzzeh B, Mongrain R, Leask R, Bertrand OF,. Evaluation of the effect of stent strut profile on shear stress distribution using statistical moments. Biomed Eng Online 2009; 8: 8.
15. Kurmasheva RT, Huang S, Houghton PJ,. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 2006; 95: 955-960.
16. Huang S, Bjornsti MA, Houghton PJ,. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2: 222-232.
17. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB,. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100: 1872-1878.
18. Freed FS, Safian RD,. Proximal vessel tortuosity and angulated lesions. In:, Safian RD, Freed MS, editors. Manual of Interventional Cardiology. 3rd edition. Royal Oak, MI: Physician's Press; 2001. pp. 237-243.
19. Ino Y, Toyoda Y, Tanaka A, Ishii S, Kusuyama Y, et al. Predictors and prognosis of stent fracture after sirolimus-eluting stent implantation. Circ J 2009; 73: 2036-2041.
20. Umeda H, Gochi T, Iwase M, Izawa H, Shimizu T, Ishiki R, Inagaki H, Toyama J, Yokota M, Murohara T,. Frequency, predictors and outcome of stent fracture after sirolimus-eluting stent implantation. Int J Cardiol 2009; 133: 321-326.
21. Zhang F, Dong L, Ge J,. Meta-analysis of five randomized clinical trials comparing sirolimus-versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol 2010; 105: 64-68.
22. Rathore S, Terashima M, Katoh O, Matsuo H, Tanaka N, et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: Contemporary practice in real world patients. EuroIntervention 2009; 5: 349-354.
23. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010; 121: e46-e215.
24. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB,. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003; 22: 7280-7295.
25. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41: 1283-1288.
26. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A,. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103: 2816-2821.
27. Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv 2007; 69: 380-386.
28. Freixa X, Almasood AS, Khan SQ, Wainstein R, Osherov A, Mackie K, Seidelin PH, Dzavik V,. Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: Results of long-term follow-up. Catheter Cardiovasc Interv 2012; 79: 559-565
29. Lemos PA, van Mieghem CA, Arampatzis CA, Hoye A, Ong AT, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: Late angiographic and clinical outcomes. Circulation 2004; 109: 2500-2502.